Table 2.
Demographic characteristics and immunosuppressive drug treatment of study participants.
| Cohort | T1-cohort (total) |
T1-cohort (T2 match subset) |
T2-cohort |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient type | CR | Stable | TOL | CR | Stable | TOL | CR | Stable | TOL |
| Number | 34 | 186 | 18 | 15 | 43 | 12 | 15 | 43 | 12 |
| T1-T2 timea | – | – | – | – | – | – | 6⋅4 (3⋅0) | 7⋅1 (3⋅2) | 5⋅4 (2⋅3) |
| Agea | 44⋅7 (14⋅4) | 50⋅7 (13⋅2) | 48⋅5 (14⋅2) | 44⋅3 (14⋅7) | 48⋅9 (13⋅0) | 50⋅3 (15⋅1) | 44⋅8 (14⋅5) | 49⋅4 (13⋅1) | 50⋅9 (14⋅9) |
| Time from Txa | 9⋅5 (7⋅1) | 14⋅8 (7⋅9) | 19⋅0 (8⋅1) | 6⋅3 (4⋅0) | 15⋅1 (6⋅9) | 20⋅8 (8⋅7) | 6⋅8 (4⋅0) | 15⋅6 (6⋅9) | 21⋅2 (8⋅6) |
| eGFRa | 33⋅1 (12⋅7) | 63⋅9 (22⋅9) | 60⋅4 (15⋅7) | 33⋅3 (11⋅4) | 61⋅3 (25⋅7) | 61⋅7 (12⋅5) | 32⋅2 (10⋅3) | 58⋅6 (20⋅1) | 66⋅8 (21⋅1) |
| Femaleb | 11 (32⋅4) | 60 (32⋅3) | 4 (22⋅2) | 4 (26⋅7) | 12 (27⋅9) | 2 (16⋅7) | 4 (26⋅7) | 12 (27⋅9) | 2 (16⋅7) |
| Ethnicityb | |||||||||
| White | 28 (82⋅4) | 162 (87⋅1) | 16 (88⋅9) | 11 (73⋅3) | 38 (88⋅4) | 11 (91⋅7) | 11 (73⋅3) | 38 (88⋅4) | 11 (91⋅7) |
| Asian | 1 (2⋅9) | 6 (3⋅2) | – | – | 2 (4⋅7) | – | – | 2 (4⋅7) | – |
| Black | 3 (8⋅8) | 8 (4⋅3) | – | 2 (13⋅3) | 2 (4⋅7) | – | 2 (13⋅3) | 2 (4⋅7) | – |
| Other / unknown | 2 (5⋅9) | 10 (5⋅4) | 2 (11⋅1) | 2 (13⋅3) | 1 (2⋅3) | 1 (8⋅3) | 2 (13⋅3) | 1 (2⋅3) | 1 (8⋅3) |
| Living donorb | 12 (35⋅3) | 57 (30⋅6) | 8 (44⋅4) | 6 (40⋅0) | 11 (25⋅6) | 7 (58⋅3) | 6 (40⋅0) | 11 (25⋅6) | 7 (58⋅3) |
| DSAb | 15 (44⋅1) | 16 (8⋅6) | 3 (16⋅7) | 6 (40⋅0) | 5 (11⋅6) | 2 (16⋅7) | 6 (40⋅0) | 5 (11⋅6) | 2 (16⋅7) |
| HLA mismatchb | |||||||||
| None | – | 18 (9⋅7) | 5 (27⋅8) | – | 2 (4⋅7) | 3 (25⋅0) | – | 2 (4⋅7) | 3 (25⋅0) |
| HLA A only | – | 8 (4⋅3) | 1 (5⋅6) | – | 2 (4⋅7) | 1 (8⋅3) | – | 2 (4⋅7) | 1 (8⋅3) |
| HLA B only | 2 (5⋅9) | 14 (7⋅5) | – | – | 3 (7⋅0) | – | – | 3 (7⋅0) | – |
| HLA DR only | 1 (2⋅9) | 1 (0⋅5) | – | 1 (6⋅7) | 1 (2⋅3) | – | 1 (6⋅7) | 1 (2⋅3) | – |
| HLA A and B | 8 (23⋅5) | 39 (21⋅0) | 2 (11⋅1) | 6 (40⋅0) | 6 (14⋅0) | 1 (8⋅3) | 6 (40⋅0) | 6 (14⋅0) | 1 (8⋅3) |
| HLA A and DR | 3 (8⋅8) | 12 (6⋅5) | – | 1 (6⋅7) | 5 (11⋅6) | – | 1 (6⋅7) | 5 (11⋅6) | – |
| HLA B and DR | 3 (8⋅8) | 13 (7⋅0) | – | 2 (13⋅3) | 5 (11⋅6) | – | 2 (13⋅3) | 5 (11⋅6) | – |
| HLA A, B and DR | 14 (41⋅2) | 60 (32⋅3) | 7 (38⋅9) | 4 (26⋅7) | 11 (25⋅6) | 5 (41⋅7) | 4 (26⋅7) | 11 (25⋅6) | 5 (41⋅7) |
| Unknown | 3 (8⋅8) | 21 (11⋅3) | 3 (16⋅7) | 1 (6⋅7) | 8 (18⋅6) | 2 (16⋅7) | 1 (6⋅7) | 8 (18⋅6) | 2 (16⋅7) |
| IS drugsb | |||||||||
| On PRED | 24 (70⋅6) | 78 (41⋅9) | – | 10 (66⋅7) | 23 (53⋅5) | – | 11 (73⋅3) | 23 (53⋅5) | – |
| Off CNI | 2 (5⋅9) | 34 (18⋅3) | 18 (100) | 1 (6⋅7) | 7 (16⋅3) | 12 (100) | 1 (6⋅7) | 7 (16⋅3) | 12 (100) |
| On CYC | 4 (11⋅8) | 96 (51⋅6) | – | 1 (6⋅7) | 25 (58⋅1) | – | 1 (6⋅7) | 25 (58⋅1) | – |
| On TAC | 28 (82⋅4) | 56 (30⋅1) | – | 13 (86⋅7) | 11 (25⋅6) | – | 13 (86⋅7) | 11 (25⋅6) | – |
| Off AP | 6 (17⋅6) | 33 (17⋅7) | 18 (100) | 3 (20⋅0) | 11 (25⋅6) | 12 (100) | 2 (13⋅3) | 11 (25⋅6) | 12 (100) |
| On AZA | 5 (14⋅7) | 67 (36⋅0) | – | 3 (20⋅0) | 15 (34⋅9) | – | 3 (20⋅0) | 15 (34⋅9) | – |
| On MMF | 23 (67⋅6) | 86 (46⋅2) | – | 9 (60⋅0) | 17 (39⋅5) | – | 10 (66⋅7) | 17 (39⋅5) | – |
| IS drug dosesc | |||||||||
| PRED | 5⋅0 (3⋅1) | 5⋅0 (0) | – | 6⋅9 (5⋅0) | 5⋅0 (1⋅0) | – | 7⋅5 (5⋅0) | 5⋅0 (2⋅2) | – |
| CYC | 150 (19) | 150 (100) | – | 125 (0) | 125 (125) | – | 200 (0) | 150 (100) | – |
| TAC | 4⋅5 (2⋅1) | 3⋅8 (3⋅0) | – | 5⋅0 (6⋅0) | 4⋅0 (1⋅5) | – | 5⋅0 (4⋅5) | 4⋅0 (2⋅0) | – |
| AZA | 100 (75) | 100 (50) | – | 150 (25) | 75 (62) | – | 150 (25) | 75 (62) | – |
| MMF | 1000 (750) | 1000 (500) | – | 1037 (1000) | 1000 (500) | – | 509 (1390) | 1000 (500) | – |
– summarised with mean (standard deviation);
– summarised with number (percentage from total in group);
– summarised with median (interquartile range) for patients receiving the corresponding drug; Age – age at sample collection (years); AP – anti-proliferative; AZA – azathioprine; CNI – calcineurin inhibitor; CYC – cyclosporin; CR – chronic rejector kidney transplant recipients (KTRs); DSA – donor specific antibodies; eGFR – estimated glomerular filtration rate; HLA – human leucocyte antigens; IS – immunosuppressive; KTRs – kidney transplant recipients; MMF – mycophenolate-mofetil; PRED – prednisolone; TAC – tacrolimus; TOL – KTRs with operational tolerance; T1-T2 time – time between timepoints 1 and 2 (months); Time from Tx – time from transplantation (years); T1-cohort – participants at baseline; T2-cohort – participants from T1-cohort with a follow-up sample; T1-cohort (T2 match subset) – the subset of the cohort at time point one that included only the patients providing samples in both time points; Two of the 12 healthy controls were women and the mean age at sample collection was 49•3 (standard deviation=12•8) years. eGFR was available for 12 TOL, 173 stable and 31 CR KTRs from T1-cohort and for 10 TOL, 40 stable and 14 CR KTRs from T2-cohort. KTRs were recruited in 14 transplant centres and samples were collected between September 2009 and December 2014 [6].